Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Boehringer Ingelheim will pay South Korea’s Yuhan $40 million to jointly develop a treatment for nonalcoholic steatohepatitis (NASH) and related liver diseases. Companies are developing numerous therapies to treat NASH, a serious liver disorder marked by fat accumulation, inflammation, and scarring. While most treatments in development address one of those three traits, Yuhan’s molecule, a dual agonist of GLP-1 and FGF21, aims to address both inflammation and scarring.
This article has been sent to the following recipient: